Terms: = Breast cancer AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Prognosis
16 results:
1. Dysregulated ceramides metabolism via ptpn11 exposes a metabolic vulnerability to breast cancer metastasis.
Qiao S; Wang T; Wang H
Med Oncol; 2023 Sep; 40(11):310. PubMed ID: 37773553
[TBL] [Abstract] [Full Text] [Related]
2. A pan-cancer analysis confirms ptpn11's potential as a prognostic and immunological biomarker.
Cao Y; Duan H; Su A; Xu L; Lai B
Aging (Albany NY); 2022 Jul; 14(13):5590-5610. PubMed ID: 35802774
[TBL] [Abstract] [Full Text] [Related]
3. shp2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability
Yuan Y; Fan Y; Gao Z; Sun X; Zhang H; Wang Z; Cui Y; Song W; Wang Z; Zhang F; Niu R
Cancer Biol Med; 2020 Aug; 17(3):707-725. PubMed ID: 32944401
[No Abstract] [Full Text] [Related]
4. Advances in molecular mechanisms of drugs affecting abnormal glycosylation and metastasis of breast cancer.
Liu H; Ma L; Lin J; Cao B; Qu D; Luo C; Huang W; Han L; Xu H; Wu Z; Xu R; Zhang D
Pharmacol Res; 2020 May; 155():104738. PubMed ID: 32151681
[TBL] [Abstract] [Full Text] [Related]
5. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H
Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616
[TBL] [Abstract] [Full Text] [Related]
6. MPZL1 forms a signalling complex with GRB2 adaptor and ptpn11 phosphatase in HER2-positive breast cancer cells.
Beigbeder A; Chartier FJM; Bisson N
Sci Rep; 2017 Sep; 7(1):11514. PubMed ID: 28912526
[TBL] [Abstract] [Full Text] [Related]
7. shp2 Plays a Critical Role in IL-6-Induced EMT in breast cancer Cells.
Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810
[TBL] [Abstract] [Full Text] [Related]
8. A novel double-negative feedback loop between miR-489 and the HER2-shp2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
[TBL] [Abstract] [Full Text] [Related]
9. Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway.
Alshaker H; Krell J; Frampton AE; Waxman J; Blyuss O; Zaikin A; Winkler M; Stebbing J; Yagüe E; Pchejetski D
Breast Cancer Res; 2014 Oct; 16(5):426. PubMed ID: 25482303
[TBL] [Abstract] [Full Text] [Related]
10. Tyrosine phosphatase shp2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.
Sausgruber N; Coissieux MM; Britschgi A; Wyckoff J; Aceto N; Leroy C; Stadler MB; Voshol H; Bonenfant D; Bentires-Alj M
Oncogene; 2015 Apr; 34(17):2272-8. PubMed ID: 24931162
[TBL] [Abstract] [Full Text] [Related]
11. Src homology phosphotyrosyl phosphatase-2 expression is an independent negative prognostic factor in human breast cancer.
Muenst S; Obermann EC; Gao F; Oertli D; Viehl CT; Weber WP; Fleming T; Gillanders WE; Soysal SD
Histopathology; 2013 Jul; 63(1):74-82. PubMed ID: 23672411
[TBL] [Abstract] [Full Text] [Related]
12. Tyrosine phosphatase shp2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
[TBL] [Abstract] [Full Text] [Related]
13. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells.
Johnson KJ; Peck AR; Liu C; Tran TH; Utama FE; Sjolund AB; Schaber JD; Witkiewicz AK; Rui H
Am J Pathol; 2010 Dec; 177(6):2971-83. PubMed ID: 20952588
[TBL] [Abstract] [Full Text] [Related]
14. shp2 mediates the localized activation of Fyn downstream of the α6β4 integrin to promote carcinoma invasion.
Yang X; Dutta U; Shaw LM
Mol Cell Biol; 2010 Nov; 30(22):5306-17. PubMed ID: 20855525
[TBL] [Abstract] [Full Text] [Related]
15. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival.
Gong YP; Yarrow PM; Carmalt HL; Kwun SY; Kennedy CW; Lin BP; Xing PX; Gillett DJ
Eur J Surg Oncol; 2007 May; 33(4):438-43. PubMed ID: 17125961
[TBL] [Abstract] [Full Text] [Related]
16. Transient detection of beta-galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy.
Bagnis C; Chabannon C; Gravis G; Imbert AM; Maroc C; Bardin F; Ladaique P; Viret F; Genre D; Faucher C; Stoppa AM; Vey N; Blaise D; Maraninchi D; Viens P; Mannoni P
Exp Hematol; 2002 Feb; 30(2):108-15. PubMed ID: 11823045
[TBL] [Abstract] [Full Text] [Related]
